A Phase 1 interventional study of vorinostat and Comparator: placebo (unspecified) in Advanced Cancer Relapsed and Advanced Cancer Refractory, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.
Merck Duration of Treatment : vorinostat; treatment will continue until disease progression or intolerable toxicity is reached
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm A: Drug/Placebo
Drug: vorinostat · Drug: Comparator: placebo (unspecified)
Arm B: Placebo/Drug
Drug: vorinostat · Drug: Comparator: placebo (unspecified)
A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
Also known as: MK0683, Zolinza®
A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
Change From Baseline in QTcF at 0.5 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 0.5 hours
Change From Baseline in QTcF at 1 Hour
Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 1 hour
Change From Baseline in QTcF at 2 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 2 hours
Change From Baseline in QTcF at 3 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 3 hours
Change From Baseline in QTcF at 4 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The placebo-corrected change from baseline in QTcF was calculated by subtracting the QTcF change from baseline for placebo at each timepoint from the QTcF change from baseline for vorinostat at each timepoint.
Time frame: Baseline and 4 hours
Change From Baseline in QTcF at 8 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 8 hours
Change From Baseline in QTcF at 12 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 12 hours
Change From Baseline in QTcF at 24 Hours
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
Time frame: Baseline and 24 hours
Eric Rubin, M.D., The Cancer Institute of New Jersey, New Brunswick, New Jersey; Pamela Munster, M.D., H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Prof. Dr. Simon van Belle, University Hospital of Ghent, Ghent, Belgium. Dosing initiated on 16-Jul-2007 and completed on 05-Feb-2009.
| Milestone | Vorinostat Then Placebo: Part 1 | Placebo Then Vorinostat: Part 1 | All Participants: Part 2 |
|---|---|---|---|
| Started | 13 | 12 | 0 |
| Completed | 11 | 12 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Milestone | Vorinostat Then Placebo: Part 1 | Placebo Then Vorinostat: Part 1 | All Participants: Part 2 |
|---|---|---|---|
| Started | 11 | 12 | 0 |
| Completed | 11 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Vorinostat Then Placebo: Part 1 | Placebo Then Vorinostat: Part 1 | All Participants: Part 2 |
|---|---|---|---|
| Started | 11 | 12 | 0 |
| Completed | 11 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Vorinostat Then Placebo: Part 1 | Placebo Then Vorinostat: Part 1 | All Participants: Part 2 |
|---|---|---|---|
| Started | 12 | 12 | 0 |
| Completed | 12 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Vorinostat Then Placebo: Part 1 | Placebo Then Vorinostat: Part 1 | All Participants: Part 2 |
|---|---|---|---|
| Started | 0 | 0 | 24 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 24 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 17 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 0.5 Hours | 1.78 (-1.53 to 5.09) | -1.22 (-4.53 to 2.08) |
Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 1 Hour | 0.22 (-3.09 to 3.52) | -1.23 (-4.54 to 2.08) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 2 Hours | 1.09 (-2.22 to 4.40) | -1.98 (-5.23 to 1.28) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 3 Hours | 1.32 (-1.99 to 4.63) | -1.52 (-4.77 to 1.73) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The placebo-corrected change from baseline in QTcF was calculated by subtracting the QTcF change from baseline for placebo at each timepoint from the QTcF change from baseline for vorinostat at each timepoint.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 4 Hours | 4.95 (1.64 to 8.26) | -1.49 (-4.75 to 1.76) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 8 Hours | -3.56 (-6.87 to -0.25) | -7.89 (-11.20 to -4.58) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 12 Hours | 1.35 (-2.08 to 4.78) | -1.31 (-4.62 to 2.00) |
The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value.
| milliseconds | Vorinostat | Placebo |
|---|---|---|
| Change From Baseline in QTcF at 24 Hours | 1.53 (-1.84 to 4.98) | -4.89 (-8.29 to -1.67) |
Collected over Reported adverse experiences are those from the time patients began study treatment until the patient discontinued. The average AE reporting timeframe is 78 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | 11/25 (44%) | 24/25 (96%) |
| Event | All Participants |
|---|---|
| Disease ProgressionGeneral disorders | 3/25 |
| Abdominal PainGastrointestinal disorders | 2/25 |
| VomitingGastrointestinal disorders | 2/25 |
| PyrexiaGastrointestinal disorders | 2/25 |
| AnemiaBlood and lymphatic system disorders | 1/25 |
| AscitesGastrointestinal disorders | 1/25 |
| ConstipationGastrointestinal disorders | 1/25 |
| DiarrheaGastrointestinal disorders | 1/25 |
| Small Intestinal ObstructionGastrointestinal disorders | 1/25 |
| FatigueGeneral disorders | 1/25 |
| Event | All Participants |
|---|---|
| NauseaGastrointestinal disorders | 20/25 |
| FatigueGeneral disorders | 17/25 |
| AnorexiaMetabolism and nutrition disorders | 16/25 |
| ConstipationGastrointestinal disorders | 12/25 |
| VomitingGastrointestinal disorders | 10/25 |
| DiarrheaGastrointestinal disorders | 9/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/25 |
| Dry MouthGastrointestinal disorders | 6/25 |
| Taste ChangedNervous system disorders | 6/25 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 59.4 (29 to 78) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 12 |
| Male | 13 |
| Race/Ethnicity, Customized(participants) | All Participants |
|---|---|
| Asian | 1 |
| Black | 2 |
| Hispanic | 1 |
| White | 21 |
| Cancer Type(Participants) | All Participants |
|---|---|
| Ovarian | 5 |
| Colon | 3 |
| Lung | 3 |
| Mesothelioma | 3 |
| Uterine | 2 |
| Soft Tissue | 2 |
| Anal | 1 |
| Basocellular | 1 |
| Breast | 1 |
| Gastrointestinal | 1 |
| Mucinous carcinoma | 1 |
| Pancreatic | 1 |
| Thyroid | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | All Participants |
|---|---|
| 0 = Normal Activity | 9 |
| 1 = Symptoms, but ambulatory | 13 |
| 2 = In bed <50% of the time | 3 |
| Number of Prior Radiation Therapies(Participants) | All Participants |
|---|---|
| None | 14 |
| One Prior Radiation Therapy | 7 |
| Two Prior Radiation Therapies | 1 |
| Three or More Prior Radiation Therapies | 3 |
| Number of Prior Systemic Anti-Cancer Therapies(Participants) | All Participants |
|---|---|
| One Prior Systemic Anti-Cancer Therapy | 0 |
| Two Prior Systemic Anti-Cancer Therapies | 3 |
| Three or more Prior Systemic Anti-Cancer Therapies | 22 |
No study locations are listed for this record.
The record gives a start of Jul 2007, a primary completion of May 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat